Join us this week as we sit down with Daniele Foresti, CEO and Co-Founder of Acoustica Bio and Jasper Neggers, PhD, Founder and Chief Scientific Officer of Promakhos Therapeutics.
The Lab-to-Launch Lounge (LLL) series brings Harvard graduate students in CxO roles back to campus to hear how they launched their research out from Harvard labs:
 * how did they get here
 * what would they do differently--and what they would not do at all--if a student again
  * anything else on your mind
Â
Join the discussion, meet fun people, grab a bite, and leave with new ideas. Open to the Harvard community.
Â
Images above are all original creations by DALL·E 2, representing the intersection of science, engineering, and organic conversations in a casual lounge environment.
Â
Connect with us:
Lemann Program on Creativity and Entrepreneurship
Center for Technology Entrepreneurship
2Â hours: 4-6pm.
CEO and Co-Founder of Acoustica Bio
Daniele is the founder and inventor of AcousticaBio technology which brings life-saving drug delivery from hospital to home. He earned his PhD in Mechanical Engineering from ETH Zürich. Daniele introduced a new fluid processing technology that can revolutionize manufacturing in life science and beyond.
Co-Founder and Chief Scientific Officer, Promakhos Therapeutics
Jasper Neggers is the co-founder and CSO of Promakhos Therapeutics. Jasper arrived in the USA as a postdoctoral fellow at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard to identify and validate new therapeutic targets for cancer. His work has nominated several new high-priority therapeutic targets and has led to the initiation of new drug discovery campaigns. Before that, Jasper performed his Ph.D. studies at the Rega Institute for Medical Research at the KU Leuven, Belgium. He was among the first scientists to apply CRISPR/Cas to genetically engineer human cells and validated the mechanism of action of the anticancer drug Selinexor (XPOVIO®) for the first time in human cells. In Belgium, Jasper also invented a new CRISPR genetic screening approach for uncovering the mechanisn of new drugs. However, ultimately, Jasper wants his research to translate into patient impact and felt that an academic career would not provide the right environment to pursue his vision, hence he cofounded Promakhos Therapeutics.